Robert Hamilton Pierce
Chief Scientific OfficerDr. Robert Hamilton Pierce, also known as Rob, M.D., is Member of Scientific Advisory Board of Yatiri Bio, Inc. Dr. Pierce is Fractional Executive of Aloe Therapeutics Inc. Dr. Pierce is Chief Scientific Officer of Ernexa Therapeutics Inc. (formerly known as Eterna Therapeutics Inc.) from August 2024. He serves as Chief Medical Officer at Attivare Therapeutics Inc. He served as Chief R&D Officer at Sensei Biotherapeutics Inc. since January 2022 until December 7, 2022 and was its Chief Scientific Officer since March 2020 until January 2022. He serves as Chief Scientific Officer at Alvaxa Biosciences, Incorporated. Dr. Pierce served as the Chairman of the Scientific Advisory Board, Consultant and Chief Scientific Strategist at OncoSec Medical Incorporated since June 18, 2016. Dr. Pierce served as the Chief Scientific Officer and Global Head of R&D at OncoSec Medical Incorporated since September 16, 2014 until June 18, 2016. Dr. Pierce served as the Chief Medical Officer of OncoSec Medical Incorporated since December 12, 2013 until September 16, 2014. He served as a Discovery Project Team Leader for two novel drug candidates. He served as an Executive Director of Merck Research Labs. Dr. Pierce served at Merck Research Labs -- Palo Alto where he worked in leading a 20--person team, dedicated to developing disease-oriented and tissue-based translational medicine platforms. From 2001 to 2007, he served several leadership positions at the University of Rochester School of Medicine, including Director of the Autopsy Service at Strong Memorial Hospital. Dr. Pierce was at Merck Research abs. He focused on immunomodulatory receptor (IMR) programs. He practiced as a staff pathologist to develop the graduate curriculum in pathomechamism of disease. He was the Principal investigator of a RO1-funded research lab, Dr. Pierce played an important role in the university's clinical and academic research programs. He is the co-author of over fifty peer-reviewed journal articles and book chapters and is a reviewer for numerous scientific journals as well as National Institute of Health grants. Dr. Pierce is well regarded for his career-long research into mechanisms of immune tolerance and has drug development experience. He is a key Member of the global development team behind Merck's FDA-designated breakthrough anti-PD-1 program (MK-3475). He was a Fulbright Award recipient. He studied Philosophy at the Albert-Ludwigs-University in Freiburg, Germany. He had been a Member of Scientific Advisory Board at Immunomic Therapeutics, Inc. since January 05, 2017. He serves as a Member of the Fred Hutchinson Cancer Research Center and the Scientific Director of the Immunopathology Lab from November 2016 until March 2020. Dr. Pierce received a B.A. in Philosophy from Yale College and an M.D. from Brown University. Dr. Pierce received his Post-Doctoral Training at the University of Washington, Seattle, WA. He trained at Brown University School of Medicine in Providence, RI and received an Undergraduate Education at Yale University in New Haven, CT.
Positions
- Company NameErnexa Therapeutics Inc.Stock CodeERNAPositionChief Scientific OfficerRelated SecuritiesColleagues
- SLSanjeev LutherCEO, President & Director
- JAJames A. BristolIndependent Chairman of the Board
- MJMark J. KeeleyChief Financial Officer
- DVDeborah Vee WildHead of CMC & Operations
- DJDorothy J. ClarkeGeneral Counsel
- WAWilliam A. WexlerIndependent Director
- CRChristopher RohdeMember of Scientific Advisory Board
- MAMichael AndreeffMember of Scientific Advisory Board
